title: Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hépatites virales CO3 Aquitaine Cohort.
abstract: BACKGROUND
  Hepatic steatosis is a common feature in liver biopsies from patients with chronic hepatitis C and is associated with fibrosis progression. Patients with HIV infection and hepatitis C virus (HCV) coinfection have more rapid progression of liver fibrosis than patients with HCV infection alone. The prevalence and factors associated with hepatic steatosis are not well defined in HCV-HIV-coinfected patients.
  
  
  METHODS
  Steatosis was assessed among 148 HCV-HIV-coinfected patients of the Aquitaine Cohort. Steatosis was graded as follows: none, mild (1%-10% of hepatocytes), moderate (11%-30%), severe (31%-60%), and massive (more than 60%). Epidemiologic, clinical, biologic, and therapeutic data were retrieved from the cohort database to investigate the risk factors.
  
  
  RESULTS
  Steatosis was present in 67% of patients (95% confidence interval [CI]: 59% to 74%) and was at least moderate in 30% (95% CI: 23% to 38%). Steatosis was macrovesicular or mixed (macro- and microvesicular) in 40.5% and 52.8% of patients, respectively. Necroinflammatory activity was the only factor independent of steatosis (adjusted odds ratio = 5.3, 95% CI: 1.6 to 17.9). When necroinflammatory activity was removed from the model, HCV genotype 3 and body mass index (BMI) were significantly associated with steatosis.
  
  
  CONCLUSIONS
  Liver inflammation, HCV genotype 3, and BMI are associated with steatosis, a common finding in HCV-HIV-coinfected patients.
authors.affiliation: Fédération des Maladies Infectieuses et Tropicales, Centre Hospitalo-Universitaire, Hôpital Pellegrin, Bordeaux, France. didier.neau@chu-bordeaux.fr
authors.forename: Didier
authors.initials: D
authors.lastname: Neau
authors.forename: Maria
authors.initials: M
authors.lastname: Winnock
authors.forename: Laurent
authors.initials: L
authors.lastname: Castéra
authors.forename: Brigitte Le
authors.initials: BL
authors.lastname: Bail
authors.forename: Marc-Arthur
authors.initials: MA
authors.lastname: Loko
authors.forename: Laurent
authors.initials: L
authors.lastname: Géraut
authors.forename: Michel
authors.initials: M
authors.lastname: Dupon
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Ragnaud
authors.forename: Denis
authors.initials: D
authors.lastname: Lacoste
authors.forename: Marie-Edith
authors.initials: ME
authors.lastname: Lafon
authors.forename: Paulette
authors.initials: P
authors.lastname: Bioulac-Sage
authors.forename: François
authors.initials: F
authors.lastname: Dabis
mesh_terms: D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D015331:Cohort Studies; D005234:Fatty Liver / Q000453:epidemiology / Q000209:etiology*; D005260:Female; D005602:France; D015658:HIV Infections / Q000150:complications* / Q000453:epidemiology; D006526:Hepatitis C / Q000150:complications* / Q000453:epidemiology / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012307:Risk Factors
chemical_list: D019380:Anti-HIV Agents